• Product NameTivozanib (AV-951)
• Brief DescriptionInhibitors
• Purification97.41%
• Biological ActivityTivozanib is an orally bioavailable inhibitor of vascular endothelial growth factor receptors (VEGFRs) 1, 2 and 3 with potential antiangiogenic and antineoplastic activities. Tivozanib binds to and inhibits VEGFRs 1, 2 and 3, which may result in the inhibition of endothelial cell migration and proliferation, inhibition of tumor angiogenesis and tumor cell death. VEGFR tyrosine kinases, frequently overexpressed by a variety of tumor cell types, play a key role in angiogenesis.
• Target NameEphrin Receptor inhibitor; PDGFR inhibitor; VEGFR inhibitor
• CAS No. 475108-18-0
• Calculated MW 454.86
• Formulation C22H19ClN4O5
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:COC1=CC2=NC=CC(OC3=CC(Cl)=C(NC(=O)NC4=NOC(C)=C4)C=C3)=C2C=C1OC
  Pathways:Angiogenesis; Tyrosine Kinase/Adaptors
  Receptor:EphB2; PDGFRα; VEGFR1; VEGFR2; VEGFR3
  Boling pt:
  Melting pt:
  Solubility:DMSO: 20 mg/mL (43.96 mM)
  Appearance:Gray Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Nakamura K, et al. Y Res, 2006, 66(18), 9134-9142.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting